Addiction
August 3, 2026
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova et al.
BACKGROUND AND AIMS: This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; BPL-003) administered alongside psychological support and manualised cognitive behavioural...
Addiction
December 10, 2025
John Marsden, Michael Kelleher, Fiona Dunbar et al.
2 citations
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive Behavioural Therapy (CBT). Design Open‐label,...
Addiction
January 30, 2025
Theodore Piper, Francesca Small, Michael Kelleher et al.
27 citations
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its quality; and to offer recommendations for...
European Addiction Research
December 18, 2006
Jim Mccambridge, Adam Winstock, Neil Hunt et al.
113 citations
<i>Aims:</i> To describe and assess trends in the use of hallucinogens and other adjunct drugs over a 5-year period. <i>Design:</i> Repeated-measures cross-sectional survey. <i>Setting and Participants:</i> Annual magazine-based survey targeting people who use drugs in dance contexts. <i>Measurements:</i> Lifetime use prevalence (ever used); age of first use; current use prevalence (any use...